BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

While many of us may think of the cold and flu viruses as a fall or winter nuisance, summer colds are actually quite common. Newly-released data is also showing a surge in COVID-19 in the U.S. this ...

This article will be updated throughout the day, so check back often for more daily updates. Last week ended on a down note — and a 2.4% weekly loss for the Vanguard S&P 500 ETF (NYSEMKT: VOO) — as a ...

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

BioNTech’s second-quarter earnings came in at a loss of 1.60 euros a share on revenue of €261 million ($302.1 million), ...

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

BioNTech said a partnership with Bristol Myers Squibb is expected to further strengthen its financial position with $1.5 billion expected to be reflected in its cash position for the current quarter.

BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.